China’s Xi speaks with Trump by phone, discusses Taiwan and bilateral ties
Amgen (NASDAQ:AMGN) Senior Vice President and Chief Commercial Officer Nancy A. Grygiel sold 3,139 shares of common stock on November 20, 2025, for a total of $1.05 million. The shares were sold at a price of $337.2625, just shy of the company’s 52-week high of $345.84. The biotechnology giant has seen impressive 33.7% price returns year-to-date and currently maintains a market capitalization of $182.4 billion, according to InvestingPro data.
On the same day, Grygiel also exercised options to acquire 3,139 shares of Amgen common stock. These transactions involved two separate option exercises, with 1,500 shares acquired at $177.46 per share and 1,639 shares acquired at $162.60 per share, for a total value of $532691.
Following these transactions, Grygiel directly owns 7,225 shares of Amgen common stock, inclusive of dividend equivalents, and indirectly owns 104.6847 shares through a 401(k) plan. Notably, Amgen has raised its dividend for 15 consecutive years and currently offers a 2.82% yield, making it attractive for income-focused investors. InvestingPro analysis suggests Amgen is currently slightly undervalued, with a "GREAT" overall financial health score. Discover Amgen’s complete financial picture and 10+ more exclusive ProTips in the comprehensive Pro Research Report.
In other recent news, Amgen reported strong third-quarter earnings, with revenues surpassing expectations by $596 million and earnings per share exceeding estimates by 62 cents. This financial performance led Cantor Fitzgerald to raise its price target for Amgen to $315, maintaining a Neutral rating. In addition, Piper Sandler also increased its price target to $381, citing positive prescription data trends for Amgen’s key products and maintaining an Overweight rating on the stock.
The company received full FDA approval for its lung cancer drug, IMDELLTRA, which demonstrated a 40% reduction in the risk of death in a Phase 3 study. Furthermore, Amgen’s cholesterol drug, Repatha, showed promising results in a Phase 3 trial by reducing the risk of heart attacks by 36% in high-risk patients. These developments reflect Amgen’s ongoing success in advancing its pharmaceutical portfolio and achieving significant milestones in clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.